
|Videos|November 12, 2021
President John Saharek on the ImprimisRx pipeline, details 3 products
Author(s)David Hutton, OTE Staff Reports
ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.
Advertisement
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times Europe's David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting, including:
- Moxi-Brom (moxifloxacin hydrochloride 0.5% and bromfenac sodium sesquihydrate 0.075%)
- Klarity-CL drops (cyclosporine 0.1% / loteprednol etabonate 0.2% ophthalmic suspension)
- Tim-Brim-Dor-Bim (prednisolone acetate 1%, gatifloxacin 0.5%, bromfenac 0.075%).
The American Academy of Ophthalmology (AAO) annual meeting was held November 12 to 15 at the Ernest N. Morial Convention Centre in New Orleans, Louisiana, United States. The event included Subspecialty Days and a virtual component for remote participation.
Related Content:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
How the ocular microbiome may shape outcomes in keratoplasty
2
Phaco-GSL outperforms in acute angle-closure glaucoma over chronic cases, 2-year study finds
3
EuDEC 2026: ectoine eye drops show meaningful symptom and tear film improvements in dry eye disease
4





















